3 Trumpled biotech bargains I'd buy today

ResMed Inc. (CHESS) (ASX:RMD), CSL Limited (ASX:CSL), and Sirtex Medical Limited (ASX:SRX) are looking attractive today.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Anything with the faintest hint of US exposure was trampled – Trumpled – by the market yesterday, taking a number of attractive businesses down to bargain prices. Here are three of my favourites:

ResMed Inc. (CHESS) (ASX: RMD) is a manufacturer and developer of Obstructive Sleap Apnoea (OSA) devices that help improve sleep quality and aid in respiration. ResMed is looking to expand into parallel industries like non-invasive ventilation (NIV) in countries with high levels of smoking and poor air quality. ResMed also sells cloud-based software applications that aid in the diagnosis of a number of conditions.

With $700 million in cash and $1 billion in debt, ResMed also has a good balance sheet and its prospects for growth are reasonable. It also appears cheaper than CSL.

CSL Limited (ASX: CSL) is perhaps the ultimate biotech, renowned for its high levels of R&D spending and almost constant share buybacks. CSL carries high levels of debt but enjoys very low interest rates and huge cash flows, making for a strong balance sheet.

CSL's growth has slowed somewhat in recent times, largely due to its size, although the company's heavy investment in developing new products should bode well for future earnings. Shares are still priced for a bright future, but I feel that those with a 10-year timeframe are unlikely to be disappointed.

Sirtex Medical Limited (ASX: SRX) – a liver cancer treatment company with no debt and decent international growth prospects, Sirtex is in a very good position to endure a wide range of market conditions. With a long growth runway ahead, Sirtex should be able to deliver attractive returns to shareholders over the next 10 years, with gradual expansion of the indications (potential uses) for its SIR-Spheres treatment. Additionally, investors don't have to worry about financial stress.

As I've written before, owning (profitable) biotech stocks should be a long term venture – 10 years or more. A Trump presidency pales into insignificance next to this kind of holding period, but the value you're seeing today is real.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »